British Journal of Ophthalmology Publishes Strong EyeArt Accuracy Results
Researchers from Moorfields Eye Hospital, Homerton NHS Trust, and University College London find EyeArt System to have 100% sensitivity in detecting vision-threatening retinopathy
LOS ANGELES–(BUSINESS WIRE)–#NHS—Eyenuk, Inc. announced today that the British Journal of Ophthalmology published the research paper titled “Diagnostic Accuracy of Diabetic Retinopathy Grading by An Artificial Intelligence-Enabled Algorithm Compared with a Human Standard for Wide-Field True-Colour Confocal Scanning and Standard Digital Retinal Images”. According to this independent research paper with authors from the Moorfields Eye Hospital NHS Foundation Trust, the University College London Institute of Ophthalmology, and the Homerton University Hospital NHS Foundation Trust, Eyenuk’s EyeArt AI Eye Screening System achieved 92%-100% sensitivity in diabetic retinopathy (DR) detection with multiple retinal imaging platforms.
A total of consecutive 1,257 patients attending annual diabetic eye screening in the UK were included in the study. The EyeArt System processed images acquired by CenterVue’s EIDON platform with state-of-the-art wide-field true-color confocal scanning technology, as well as images acquired by standard cameras in the English National Diabetic Eye Screening Programme (NDESP). The reference standard for analysis was the human grade of standard NDESP images carried out according to NDESP protocol. With EIDON images, the EyeArt System achieved sensitivities of 92.27% for any retinopathy, 99% for vision-threatening retinopathy and 100% for proliferative retinopathy. Corresponding EyeArt sensitivities for NDESP images were 92.26% for any retinopathy, 100% for vision-threatening retinopathy and 100% for proliferative retinopathy.
This study was conducted without any involvement by Eyenuk. “All processing of the screening episodes was performed by the research team. The vendor was not allowed access to the software or to the data set during the study period,” authors wrote in the publication. “With this [impressive] performance, if the [EyeArt] software were to be hypothetically deployed as a part of the English NDESP, the EyeArt could reduce the need to grade R0M0 by half when using EIDON images and by almost two-thirds when using the NDESP images, a considerable workload reduction.”
The UK has been leading the world in diabetic retinopathy screening, achieving patient uptake rates of over 80% (screening nearly 2.5 million diabetes patients annually) in England1, as compared with most parts of the world where typically less than half of diabetes patients receive annual eye screening.2 As a result, diabetic retinopathy is no longer the leading cause of blindness in the working age group in England.3
“Validation results from the world’s leading diabetic retinopathy screening program once again confirm EyeArt System’s strong diagnostic accuracy and its potential to significantly reduce human workload for DR screening,” said Kaushal Solanki, Ph.D., Founder and CEO of Eyenuk. “We are equally excited to learn that the EyeArt System is shown to be accurate and highly sensitive when used to analyze EIDON images for diabetic retinopathy screening per the English NDESP protocol. True-color wide-field confocal scanning is a novel technology, and we are confident that EyeArt performance can be further optimized for this exciting imaging innovation.”
About the EyeArt® AI Eye Screening System
The EyeArt AI Eye Screening System provides fully automated DR screening, including retinal imaging, DR grading on international standards and immediate reporting, in a single office visit during a diabetic patient’s regular exam. Once the patient’s fundus images have been captured and submitted to the EyeArt AI System, the DR screening results are available in a PDF report in less than 60 seconds.
The EyeArt AI System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). The EyeArt AI System has CE marking as a class 2a medical device in the European Union and a Health Canada license. In the U.S., the EyeArt AI System is limited by federal law to investigational use. It is designed to be General Data Protection Regulation (GDPR) and Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
About Eyenuk, Inc.
Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk’s first autonomous AI product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for autonomous detection of DR. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease. Find Eyenuk online on its website, Twitter, Facebook, and LinkedIn.
2 K. Fitch, T. Weisman, T. Engel, A. Turpcu, H. Blumen, Y. Rajput, and P. Dave. Longitudinal commercial claims-based cost analysis of diabetic retinopathy screening patterns. Am Health Drug Benefits. 2015;8(6):300–308.
3 G. Liew, M. Michaelides, C. Bunce. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open Bd. 4 (2014), Nr. 2
Frank Cheng, Chief Commercial Officer
+1 818 835 3585